Where, How, and When: Positioning Posttranslational Modification Within Type 1 Diabetes Pathogenesis

Author(s):
McLaughlin, R.J.; Spindler, M.P.; Lummel, M. van; Roep, B.O.
Published
2016
Publication type
Article / Letter to editor
Posttranslational modificationAutoimmune diseaseType 1 diabetesIslet antigensHigh-risk HLA
Date issued
2016-07-31
Language
English
Is part of
Current Diabetes Reports (2016), No. 7
hdl
1887/112810
doi
10.1007/s11892-016-0752-4